[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-368586-105":59,"doc-detail-368586-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","prostate-cancer-immunotherapy-based-strategies-an-updated-review-emphasizing-immune-checkpoint-inhibitors","Prostate cancer immunotherapy-based strategies - an updated review emphasizing immune checkpoint inhibitors","","Prostate cancer is a highly prevalent malignancy in older men, and current standard approaches such as chemotherapy, radiotherapy, androgen deprivation therapy (ADT), and surgery face substantial risks of recurrence and progression. Immunotherapy has gained major attention because it engages immune responses using cytokines, cell therapy, and antibody-based methods, particularly immune checkpoint inhibitors (ICIs). This review updates standard therapeutic efficacy and risk factors, then surveys immunotherapy types with an emphasis on ICIs.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/prostate-cancer-immunotherapy-based-strategies-an-updated-review-emphasizing-immune-checkpoint-inhibitors/368586/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/prostate-cancer-immunotherapy-based-strategies-an-updated-review-emphasizing-immune-checkpoint-inhibitors/368586.png","ImageObject",300,407,{"name":92,"@type":93},"Melati","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-05","2026-09-23",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is immunotherapy important in prostate cancer management?","Question",{"text":112,"@type":113},"Immunotherapy treats cancer by modulating immune system responses. It includes cytokines, cell therapies, and antibody-based approaches that can target prostate cancer cells more effectively, particularly through ICIs.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What are the major limitations of current standard treatments for prostate cancer?",{"text":117,"@type":113},"Common treatments such as chemotherapy, radiotherapy, ADT, and surgery can be followed by disease recurrence, with many patients progressing to more difficult-to-treat stages, such as castration-resistant disease.",{"name":119,"@type":110,"acceptedAnswer":120},"How does the review organize its discussion of treatments?",{"text":121,"@type":113},"It first updates standard therapeutic efficacy and risk factors, then reviews different types of immunotherapies with a focus on immune checkpoint inhibitors.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},368586,1790873499,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},962085570644,"https://ap-avatar.wpscdn.com/davatar_994ba38a5ba835b3df7d355c54d3ed8d","TYPE Review  \nPUBLISHED 18 June 2025  \nDOI 10.3389/fimmu.2025.1583363  \nOPEN ACCESS  \nEDITED BY  \nFeifei Sun,  \nShandong University, China  \nREVIEWED BY  \nGuanwen Zhou, Shandong University, China Lin Zhang,  \nBinzhou Center for Disease Control and Prevention, China  \n*CORRESPONDENCE  \nWenchao Zhang  \n [zwenchao0108@gmail.com](zwenchao0108@gmail.com)  \nRECEIVED 25 February 2025  \nACCEPTED 20 May 2025  \nPUBLISHED 18 June 2025  \nCITATION  \nLu H, Teng Z, Wang J and Zhang W (2025) Prostate cancer immunotherapy-based strategies: an updated review emphasizing immune checkpoint inhibitors.  \nFront. Immunol. 16:1583363 .  \ndoi: 10.3389/fimmu.2025.1583363  \nCOPYRIGHT  \n© 2025 Lu, Teng, Wang and Zhang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY) . The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.  \nProstate cancer immunotherapybased strategies: an updated review emphasizing immune checkpoint inhibitors  \nHua Lu 1, Zhaojun Teng 1, Jiajia Wang 2 and Wenchao Zhang 1*  \n1 Department of Urology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China, 2 Department of Oncology, Qilu Hospital of Shandong University Dezhou Hospital, Dezhou, China  \nProstate cancer (PC) is one of the most common cancers that is diagnosed in about 10-15% of men in old age. It seems that the current treatments are not effective, and this leads to prostate cancer becoming the second-deadliest cancer. Treatments such as chemotherapy, radiotherapy, androgen deprivation therapy (ADT), and surgery are among these treatments. However, the possibility of disease recurrence after these treatments is high. Therefore, other methods have become necessary, and PC treatment is changing. One of the methods that has received much attention today is immunotherapy. Immunotherapy includes all interventions that help to treat cancer or any other disease by affecting the immune system ’s responses. For this purpose, cytokines, cell therapy, and antibody-based methods can be used. Antibody-based treatments include immune checkpoint inhibitors (ICIs), and due to the high expression of immune checkpoint (ICP) molecules on the surface of prostate cancer cells and cancer stromal cells, these treatments have yielded promising results. Also, combining them with chemotherapy, surgery, and radiotherapy can help increase their efﬁciency. This review ﬁrst updates standard treatments ’therapeutic efﬁcacy and risk factors. Then, we will talk about different types of immunotherapies, emphasizing ICIs.  \nKEYWORDS  \nprostate cancer, immunotherapy, immune checkpoint inhibitors, treatment, combined therapy  \n1 Introduction  \nMetastatic prostate cancer (PC) is a leading cause of morbidity and mortality (1) . Androgen deprivation therapy (ADT) remains the cornerstone of treatment for nonmetastatic prostate cancer (2) . However, most of these patients will progress to CRPC, which is very difﬁcult to treat (3). There is, however, an intermediate stage where, following ADT, patients have cancer progression without detectable metastasis, termed nonmetastatic castration-resistant prostate cancer (nmCRPC) (4) . Awareness of nmCRPC is increasing because of ADT’s increased utilization and failure. Men with nmCRPC have a  \nFrontiers in Immunology 01 [frontiersin.org](frontiersin.org)  \nhigh risk of progressing to metastatic castration-resistant prostate cancer (mCRPC) and thus have limited treatment options (5) . However, some treatments have recently been found beneﬁcial, including three nonsteroidal antiandrogen agents under phase III trials (6) . These agents are now FDA-approved, offering effective options alongside ADT for nmCRPC patients. The treat","cbCaiai2EYGjuIlG","https://ap.wps.com/l/cbCaiai2EYGjuIlG","pdf",3206309,22,"English","# Introduction\n## Androgen deprivation therapy and disease progression\n## Immunotherapy and immune checkpoint inhibitors\n## Adoptive cell therapy","[{\"question\":\"Why is immunotherapy important in prostate cancer management?\",\"answer\":\"Immunotherapy treats cancer by modulating immune system responses. It includes cytokines, cell therapies, and antibody-based approaches that can target prostate cancer cells more effectively, particularly through ICIs.\"},{\"question\":\"What are the major limitations of current standard treatments for prostate cancer?\",\"answer\":\"Common treatments such as chemotherapy, radiotherapy, ADT, and surgery can be followed by disease recurrence, with many patients progressing to more difficult-to-treat stages, such as castration-resistant disease.\"},{\"question\":\"How does the review organize its discussion of treatments?\",\"answer\":\"It first updates standard therapeutic efficacy and risk factors, then reviews different types of immunotherapies with a focus on immune checkpoint inhibitors.\"}]","Prostate cancer immunotherapy-based strategies - an updated review emphasizing immune checkpoint inhibitors | PDF",1790177588,55,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/28dc126d3a3b0dc56542dd0f57d853d7.webp",983,1389,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/7e26f18510b8930f72963a9ff57b2bb7.webp",982,1388,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0990a82adbc24f195d0c4a39df339598.webp",981,1386,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/e329b155bd3a71b397026145d7c4e7d8.webp",980,1385]